Target intelligence / Profile preview

Chondroitin sulfate A (CSA)

Target
CSA
Molecular classification
Receptor, Other
01

Overview

Chondroitin sulfate A (CSA), also known as chondroitin 4-sulfate, is a sulfated glycosaminoglycan (GAG) composed of alternating glucuronic acid and N-acetylgalactosamine residues sulfated at the C4 position. It is a major structural component of the extracellular matrix (ECM) in connective tissues, particularly articular cartilage, where it provides resistance to compression and maintains hydration. Beyond its structural role, CSA acts as a critical cell surface receptor and signaling molecule. Notably, it serves as the primary receptor for the sequestration of Plasmodium falciparum-infected erythrocytes in the placenta via the parasite protein VAR2CSA, making it a key target for pregnancy-associated malaria vaccines. Additionally, a tumor-specific form known as oncofetal chondroitin sulfate (ofCS) is highly expressed in various solid tumors and metastases, serving as an attractive target for cancer diagnostics and targeted therapies like antibody-drug conjugates. Exogenous chondroitin sulfate is widely used as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) to reduce joint pain and slow cartilage degeneration by inhibiting inflammatory pathways (such as NF-kB) and matrix metalloproteinases.

Other names
Chondroitin 4-sulfateChondroitin sulfate A sodiumChondroitin 4-sulfate sodiumChondroitin sulfate A disodiumOncofetal chondroitin sulfateofCS
02

Mechanism of action

Receptor binding inhibition, enzymatic degradation, targeted drug delivery, and anti-inflammatory signaling modulation

03

Biological functions

Cell adhesionExtracellular matrix organizationCell signalingOther
04

Disease associations

InfectionCancerInflammationOther
05

Safety considerations

Increased bleeding risk (especially with anticoagulants like warfarin)Asthma exacerbationPathogen contamination risk from animal-derived sourcesPotential tumor promotion in BRAF V600E-mutant melanomaHypersensitivity and allergic reactions
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Oncofetal chondroitin sulfate (ofCS) expressionVAR2CSA antibody titersJoint space narrowing (JSN)C-reactive protein (CRP)

Beyond the preview

Go deeper on Chondroitin sulfate A (CSA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chondroitin sulfate A (CSA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call